SUMMARY Twenty neutropenic patients with various haematological disorders were randomised prospectively to receive either intravenous amphotericin B alone or amphotericin B and oral amiloride 5 mg twice a day for treatment of confirmed or suspected fungal infection. Patients receiving amiloride had a significantly higher plasma potassium (p < 0 01), a significantly lower urinary potassium loss (p < 001), and required significantly less potassium chloride supplementation to maintain their plasma potassium within the normal range (p < 0O001). Amiloride was well tolerated, had no clinically important side effects, and provided effective control of plasma potassium in patients treated with amphotericin B.
Invasive fungal infections are an important cause of morbidity and mortality in neutropenic patients. Amphotericin B is the most effective drug currently available for the management of systemic fungal infections in such patients, but nephrotoxicity is a major limiting factor in its use.' The nephrotoxic effects of amphotericin B are due to combined actions on both the glomeruli and renal tubules. In particular, selective distal tubular epithelial toxicity seems to be, at least in part, responsible for the profound potassium wasting which is a major clinical side effect of treatment with amphotericin B.2"
Recent studies have also shown that amphotericin B also affects sodium flux in both the distal and transverse human colon, suggesting a further site of changed sodium/potassium exchange in patients treated with this agent. 5 The management of potassium wasting induced by amphotericin B may be difficult, and even large intravenous doses of potassium chloride may not be fully effective in correcting the hypokalaemia. As a consequence, clinical problems, especially muscle weakness and cardiac arrhythmias, are seen in a proportion of patients.
Amiloride, a pyrazine derivative, is a potassium sparing diuretic widely used in clinical practice. It increases urinary excretion of sodium and bicarbonate while decreasing urinary potassium excretion by the distal convoluted tubule.6 Amiloride also has actions outside the kidney and inhibits sodium absorption Accepted for publication 16 December 1987 from the distal colon. Furthermore, the action of amiloride on this site potentially antagonises the effects of amphotericin B.'
The aim of this study was to determine whether amiloride could prevent the hypokalaemia associated with treatment with amphotericin B.
Patients and methods
Twenty consecutive neutropenic (absolute neutrophil count < 0-5 x 109/1) patients with various haematological disorders were entered into the study over six months. The study was approved by the appropriate local ethical committees and all patients gave informed written consent. The indications for amphotericin B treatment were either evidence of invasive fungal infection diagnosed by biopsy and culture, or fever unresponsive to five days of broad spectrum antibiotics in the presence of continuing neutropenia.7
On entry into the study patients were randomised to receive either amphotericin B alone intravenously or amphotericin B intravenously with oral amiloride 5 mg twice a day. Both groups received identical combinations of broad spectrum antibiotics before entry into the study, and there was no difference in aminoglycoside administration between the two groups. Broad spectrum antibiotics were continued throughout amphotericin B treatment in all but two patients. All patients received a standard hospital diet containing 40 mmol potassium/day except one patient (case 9) in the group taking amphotericin alone who required parenteral feeding. 
Results
The two patient groups studied were broadly similar in terms of age, underlying haematological diagnosis, and duration of amphotericin B treatment (tables 1 and 2).
Plasma potassium, urinary potassium losses, and daily potassium requirements for the patients receiving amphotericin B alone and patients receiving amphotericin B with amiloride are shown in tables 1 and 2, respectively. Plasma potassium was significantly higher in the group receiving amiloride. (p < 0-01), while potassium supplementation was significantly higher in the group receiving amphotericin alone (p < 0-001). supplementation for each group are summarised in the figure.
Daily potassium balance was calculated for the two groups from measurements of daily potassium intake and daily urinary potassium losses. Patients receiving amphotericin alone showed an apparent mean daily positive potassium balance of 79 3 mmol (range + 23 mmol to + 172 mmol) while the group receiving additional amiloride showed a paradoxically smaller daily gain of 13-6 mmol (range -60 mmol to + 66 mmol).
SIDE EFFECTS
There was no clinically important side effects in the group receiving additional amiloride. Four patients developed clinically unimportant hyponatraemia with the lowest recorded plasma sodium in the range 128-125 mmol/l. Three patients in each group had a minor rise in serum creatinine which did not lead to suspension oftreatment. Hypomagnesaemia requiring correction with intravenous magnesium developed in two patients receiving amphotericin B alone and in one patient receiving amphotericin B and amiloride.
Discussion
Severe hypokalaemia is the most serious side effect of amphotericin B treatment.3 The correction of hypokalaemia is difficult and may require up to 300 mmol of potassium chloride replacement a day. Oral potassium chloride supplementation in high doses is often poorly tolerated in neutropenic patients due to associated mucositis, and large intravenous doses of potassium chloride requiring careful monitoring are therefore necessary. An agent that safely decreases potassium requirements in this group of patients would thus be clinically useful. This study has shown 496 Smith, Galloway, Reilly, Davies that amiloride significantly reduces the potassium supplementation required in patients receiving short or prolonged periods of treatment with amphotericin B.
Amiloride seems to act on transport proteins affecting the active movement of ions across cell membranes. The potassium sparing effect of amiloride on renal excretion is thought to be due to blockage of sodium reabsorption in the distal renal tubule rather than to a direct effect on potassium secretion. 6 Although not specifically addressed in the present study, this distal tubular effect is probably responsible for the reduction by amiloride of urinary potassium losses in subjects treated with amphotericin B.
The well recognised renal action of amiloride does not, however, provide a complete explanation of our data. In particular, patients receiving amphotericin B alone seem to be in gross positive potassium balance, using only urinary losses to calculate daily potassium balance. Potassium retention at this level seems unlikely in the face of the low plasma potassium concentrations observed. A more likely explanation is that potassium loss from the gastrointestinal tract in neutropenic patients is significant even in the absence of gastrointestinal symptoms. In support of this contention is the recent demonstration that amphotericin B affects ion exchange in the colon in man and that this action is potentially antagonised by amiloride. We are currently investigating the effects of amphotericin B and amiloride on gastrointestinal potassium excretion in both neutropenic patients and in a non-neutropenic control group.
The predicted effects ofamiloride on plasma sodium were, mild and did not result in clinically important hyponatraemia. Renal magnesium wasting also occurs in patients treated with amphotericin B and the associated clinical problems are well recognised.89
Amiloride has been shown to decrease renal magnesium excretion in studies on animals,'0 and our preliminary data suggest that amiloride may also reduce the urinary magnesium losses seen with treatment amphotericin B in man.
Amiloride was well tolerated by all patients and produced no clinically important side effects. Oral amiloride therefore provides a safe alternative to high dose intravenous potassium replacement in patients undergoing treatment with amphotericin B. 
